AstraZeneca PLC - Form 6-K Filing

This Form 6-K filing by AstraZeneca PLC provides an update on the company's issued share capital and voting rights as of March 31, 2026. The total number of voting rights is 1,550,980,823 ordinary shares. The filing also announces the admission of 491 additional ordinary shares to trading on the London Stock Exchange's Main Market. These shares were issued between March 20 and March 31, 2026, under the company's employee share schemes and were admitted under a block admission dated January 29, 2021. The newly admitted shares are fully fungible with the existing ordinary shares. AstraZeneca is a global, science-led biopharmaceutical company focused on oncology, rare diseases, and biopharmaceuticals.